Form 4: Iovance Biotherapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, sold shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On July 15, 2024, Friedrich Graf Finckenstein, the Chief Medical Officer of Iovance Biotherapeutics, engaged in transactions involving the company's common stock.
- Specifically, 2,813 restricted stock units (RSUs) vested, and the underlying shares were acquired.
- Simultaneously, 1,428 shares were withheld by Iovance to satisfy tax obligations related to the vesting of these RSUs at a price of $8.68 per share.
- After these transactions, Graf Finckenstein directly owns 45,871 shares of Iovance Biotherapeutics.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard transaction related to executive compensation and tax obligations, with no inherent positive or negative implications for the company's performance.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
Form 4 filings are routine disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Similar transactions are common across the biotechnology industry, where stock-based compensation is frequently used.
- Companies like Gilead Sciences, Amgen, and Biogen also see regular Form 4 filings from their executives related to stock options and RSU vesting.
- The scale of the transaction is typical for an executive at Graf Finckenstein's level.
Stakeholder Impact
- The transaction has a minimal impact on shareholders, as it is a routine sale of shares to cover tax obligations.
- Employees who hold RSUs may be interested in the details of the tax withholding process.
Key Dates
| Date | Description |
|---|---|
| January 14, 2022 | Date of grant for the reported RSUs. |
| July 15, 2024 | Date of transaction: vesting of RSUs and tax withholding. |
| July 17, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.